Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update

View at publisher Summarise with VIRAT
Authors: Leyken Wilson, Lucy M. Johnson, Daniel J. Berlau
Cited by: 0
References: 71

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Duchenne muscular dystrophy (DMD) is a severe X-linked disorder caused by mutations in the dystrophin gene, resulting in progressive skeletal muscle degeneration, loss of ambulation, and eventual cardiopulmonary failure. Although survival has improved, DMD remains incurable and associated with substantial morbidity and premature mortality. AREAS COVERED: A comprehensive literature search was conducted to examine current and prospective pharmacotherapeutics for the treatment of DMD. This review summarizes FDA-approved therapies for DMD, emphasizing mechanisms of action, clinical efficacy, and safety. Corticosteroids remain the standard of care, with newer agents, such as vamorolone offering alternative safety profiles. Mutation-specific exon-skipping therapies and adeno-associated virus-mediated microdystrophin gene transfer have expanded treatment options but show variable functional benefit and safety concerns. The recent approval of the histone deacetylase inhibitor givinostat is also discussed. Emerging strategies include next-generation gene editing, utrophin upregulation, and diverse cell-based therapies, alongside evolving approaches to cardiac management. EXPERT OPINION: Recent therapeutic expansion has been driven in part by accelerated regulatory pathways relying on surrogate endpoints. While these advances provide important access, long-term efficacy, and safety data remain limited. Future progress will likely require rigorous clinical outcomes and rational combination of multimodal treatment strategies.

Fields of Study & Subjects

Muscle Physiology and Disorders Neurogenetic and Muscular Disorders Research Virus-based gene therapy research

Publication details

Journal / source
Expert Opinion on Pharmacotherapy
Volume
27
Issue
4
Pages
365–378
Publication date
4 March 2026
Language
EN